According to Zacks, “Hikma Pharmaceuticals PLC develops, manufactures and markets pharmaceutical products. Its brand portfolio includes branded, injectables and generic. Branded segment offers dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system, oncology and respiratory. Injectables segment offers dosage for CNS, controlled substances, anti-infective, cardiovascular and oncology in form of liquid, semi-liquid and powdered form. Generics segment offers dosage for therapeutic including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory and hormonal. Hikma Pharmaceuticals PLC is based in London, the United Kingdom. “
A number of other brokerages also recently issued reports on HKMPF. JPMorgan Chase & Co. lowered their price target on Hikma Pharmaceuticals from GBX 3,000 ($37.48) to GBX 2,900 ($36.23) in a report on Wednesday, March 2nd. Morgan Stanley downgraded Hikma Pharmaceuticals from an “overweight” rating to an “equal weight” rating in a report on Thursday, March 3rd. Finally, Peel Hunt raised Hikma Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 20th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $1,465.50.
About Hikma Pharmaceuticals (Get Rating)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.
- Get a free copy of the StockNews.com research report on Hikma Pharmaceuticals (HKMPF)
- Institutional Support For Rockwell International Begins To Erode
- Another Buy The Dip Opportunity In Freshpet
- Inflation Wreaks Havoc On Haverty Furniture Company
- Tractor Supply Stock Should Plow Ahead
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.